Compare Walt Disney Co (DIS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs State Street SPDR S&P Biotech ETF — how do they compare? Walt Disney Co trades at $108.05 (market cap $184.79B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Walt Disney Co is far larger — about 18.3× State Street SPDR S&P Biotech ETF's market cap, and Walt Disney Co pays a 1.4% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DIS | XBI | |
|---|---|---|
Market Cap | $184.79B | $10.11B |
Volume | 13,033,550 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $116.65 | $169.55 |
52-Week Low | $92.40 | $104.99 |
Typical Hold Time | 199 Days | 38 Days |
Enterprise Value | $225.65B | — |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.21% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue grew to $94.43B in 2025, with net income surging to $12.40B, though free cash flow faces pressure from increased investments. The stock remains below the analyst consensus price target of $125.67, indicating potential upside.
The outlook is positive with strong fundamentals and analyst support, but risks include streaming competition and high capital expenditures. Investment opportunity lies in execution of the $60B parks pipeline and streaming margin expansion, balanced against macroeconomic sensitivity and execution risks.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
